scholarly journals OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 144-145
Author(s):  
S. Siebert ◽  
I. Mcinnes ◽  
M. J. Loza ◽  
K. MA ◽  
K. Leander ◽  
...  
Keyword(s):  
Acute Phase ◽  
Acute Phase Proteins ◽  
Geometric Mean ◽  
Tnf Inhibitor ◽  
Healthy Controls ◽  
Phase 3 ◽  
Two Phase ◽  
Protein Levels ◽  
Disease Characteristics ◽  
Effector Cytokines

Background:Guselkumab (GUS), an IL-23 inhibitor monoclonal antibody (Mab) that specifically binds to the IL-23p19 subunit, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients (pts) with active psoriatic arthritis (PsA) in two phase-3 studies, DISCOVER 1 & 2.1,2Previous results from a GUS PsA Phase-2 trial3and Ustekinumab (UST, anti-IL12/23p40 MAb) PsA Phase-3 trials (PSUMMIT 1 & 2)4showed associations of baseline IL-17A, IL-17F, and CRP with baseline disease characteristics, and associations of GUS-induced cytokine reductions with clinical responses.Objectives:To investigate plausible cytokine expression in PsA and alterations after exposure to GUS therapy.Methods:In DISCOVER 1 & 2, pts were treated with GUS 100 mg at Wk 0, 4, then every 8Wks (q8w); GUS 100mg q4w; or matching PBO. 21 serum biomarkers were measured in a random subset of 300 PsA pts from the DISCOVER program at Weeks (Wks) 0, 4, & 24 and in 34 healthy controls matched for age, sex, and ethnicity. Serum proteins measured were acute phase reactants CRP & SAA (Meso Scale Discovery (MSD) Platform) and inflammatory cytokines/chemokines: Th17 effector cytokines IL-17A, IL-17F, & IL-22 (Single Molecule Counting Erenna® Immunoassay Platform) and soluble ICAM-1, soluble VCAM-1, IL-6, CXCL-8, IL-10, IL-13, IL-12p70, CCL22, IFN-γ, CCL2, CCL4, TNFα, IL-1β, IL-2, IL-4 (MSD), & YKL-40 (Quantikine Immunoassay). Serum IL-17A, IL-17B, & CRP measured in the Phase-3 PSUMMIT trials of UST for PsA4were included for comparison with GUS.Results:At baseline, serum levels of acute phase proteins CRP, SAA, & IL-6, and Th17-effector cytokines IL-17A & IL-17F were elevated in pts with PsA compared with healthy controls (p<0.05, geometric mean ≥ 40% higher, FIG 1). There was no significant dysregulation in the other cytokines measured in PsA pts compared to healthy controls. Baseline IL-17A, IL-17F, IL-22, & CCL22 were significantly associated with baseline psoriasis disease activity (Body Surface Area & Psoriatic Area and Severity Index, Spearman Signed Rank p<0.05, r>0.25). Baseline CRP, SAA, IL-6, & YKL40 were significantly associated with baseline joint disease (Disease Activity Score 28-CRP, Spearman p<0.05, r>0.25). Baseline SAA, IL-6, IL-17A, & IL-17F were higher in pts with prior TNF inhibitor exposure than without (p<0.05, geometric mean ≥ 40% higher), although pts with PsA both with and without prior TNF inhibitor had higher levels than the healthy control set.GUS treatment resulted in decreases in serum CRP, SAA, IL-6, IL-17A, IL-17F, & IL-22 that were significantly greater than PBO as early as Week 4 (FIG 1). These protein levels continued to decrease through Wk 24 in GUS-treated pts with both dosing regimens (p<0.05, geometric mean decrease from baseline ≥ 33%). Further, Wk 24 IL-17A & IL-17F levels for pts treated with either dose of GUS were not significantly different from healthy controls, suggesting a normalization of peripheral effector cytokines associated with the IL-23/Th17 axis following treatment with GUS. Effects on IL-17A/IL-17F were greater in GUS treated pts than UST treated pts, while CRP levels were similar in both programs (FIG 2).Conclusion:Comprising a strong pharmacodynamic effect, GUS treatment reduced serum protein levels of acute phase and Th17-effector cytokines (whose elevations at baseline were associated with PsA disease characteristics) and achieved comparable levels to those in healthy controls. In pts with PsA, reductions of IL-17A and IL-17F by GUS were of greater magnitude than those by UST.References:[1]Deodhar et al. ACR 2019, abs #807. Arth Rheumatol. 2019;71 S10: 1386[2]Mease et al. ACR 2019, abs #L13. Arth Rheumatol. 2019;71 S10:5247[3]Siebert et al. EULAR 2019, abs #479. Ann Rheum Dis. 2019;78 S2:293[4]Siebert et al. Arth Rheumatol. 2019;71:1660Acknowledgments:NoneDisclosure of Interests:Stefan Siebert Grant/research support from: BMS, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, Janssen, Novartis, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Matthew J Loza Employee of: Janssen Research & Development, LLC, Keying Ma Employee of: Janssen Research & Development, LLC, Karen Leander, Employee of: Janssen Research & Development, LLC, Vani Lakshminarayanan Employee of: Janssen Research & Development, LLC, Carol Franks Employee of: Janssen Research & Development, LLC, Philip Cooper Employee of: Janssen Research & Development, LLC, Kristen Sweet Employee of: Janssen Research & Development, LLC

scholarly journals Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

RMD Open ◽  
2021 ◽  
Vol 7 (2) ◽  
pp. e001679
Author(s):  
Kristen Sweet ◽  
Qingxuan Song ◽  
Matthew J Loza ◽  
Iain B McInnes ◽  
Keying Ma ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Serum Protein ◽  
Acute Phase ◽  
Acute Phase Proteins ◽  
Geometric Mean ◽  
Serum Levels ◽  
Joint Disease ◽  
Baseline Serum ◽  
Amyloid A ◽  
Effector Cytokines

ObjectiveTo investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.MethodsParticipants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive protein (CRP) and serum amyloid A (SAA) and inflammatory cytokines/chemokines were measured at weeks 0, 4 and 24 in 300 study participants and 34 healthy controls (HCs). The PSUMMIT studies measured serum interleukin (IL)-17A, IL-17F and CRP after ustekinumab treatment and levels with ustekinumab versus guselkumab treatment were compared.ResultsBaseline serum levels of CRP, SAA, IL-6, IL-17A and IL-17F were elevated in participants with active PsA vs HCs (p<0.05, geometric mean (GM) ≥40% higher). Baseline T-helper cell 17 (Th17) effector cytokines were significantly associated with baseline psoriasis but not joint disease activity. Compared with placebo, guselkumab treatment resulted in decreases in serum CRP, SAA, IL-6, IL-17A, IL-17F and IL-22 as early as week 4 and continued to decrease through week 24 (p<0.05, GM decrease from baseline ≥33%). At week 24, IL-17A and IL-17F levels were not significantly different from HCs, suggesting normalisation of peripheral IL-23/Th17 axis effector cytokines postguselkumab treatment. Reductions in IL-17A/IL-17F levels were greater in guselkumab-treated versus ustekinumab-treated participants, whereas effects on CRP levels were similar.ConclusionGuselkumab treatment reduced serum protein levels of acute phase and Th17 effector cytokines and achieved comparable levels to those in HCs. In participants with PsA, reductions of IL-17A and IL-17F were of greater magnitude after treatment with guselkumab than with ustekinumab.

scholarly journals Establishment of peritoneal liquid electrophoretogram from healthy horses and horses submitted to experimentally induced intestinal obstruction

2014 ◽  
Vol 66 (3) ◽  
pp. 665-671 ◽  
Author(s):  
A.F.S. Nogueira ◽  
P.A. Di Filippo ◽  
L.A. Anai ◽  
M.C. Vieira ◽  
K.M.M.G. Simplício ◽  
...  
Keyword(s):  
Intestinal Obstruction ◽  
Acute Phase ◽  
Acute Phase Proteins ◽  
Immunoglobulin A ◽  
Control Group ◽  
Protein Levels ◽  
Sds Page ◽  
Significant Difference ◽  
Page Electrophoresis ◽  
Experimentally Induced

The initial inflammatory stages of the colic syndrome include changes known as acute phase response. The aim of this study was to contribute with the establishment of reference values concerning the electrophoretogram of peritoneal liquid from healthy horses and horses submitted to experimentally induced intestinal obstruction. Twenty-one horses were allotted in four groups: duodenal obstruction (DG), ileum obstruction (IG), left-dorsal colon obstruction (MG), and control group (CG). Peritoneal liquid was sampled before obtruction (T0), with 3 hours of obstruction (T3) and 6, 30, 102 and 174 hours after desobstructing (T6, T30, T102 and T174, respectively). Total protein levels were determined by the biuret method and protein fractions were obtained by SDS-PAGE electrophoresis. The acute phase proteins (APP) identified were Immunoglobulin-A, ceruloplasmin, transferrin, albumin, α1-antitrypsin, heavy and light chains of immunoglobulin-G, haptoglobin, α1-acid glycoprotein and a still unnamed protein, which was called P24. There was no difference (P>0.3) in protein levels among groups, although a significant difference (P>0.05) was observed between distinct experimental moments in each group evidencing a higher response of the APP in the obstructed groups. The APP fractioning of the peritoneal liquid was standardized to establish a standard curve for healthy equines and those submitted to induced intestinal obstruction. Moreover, it was verified that the SDS-PAGE electrophoresis was sensitive and effective to help diagnose abdominal inflammatory processes.

Plasma and Breast Milk Vitamin A as Indicators of Vitamin A Status in Pregnant Women

2000 ◽  
Vol 70 (6) ◽  
pp. 271-277 ◽  
Author(s):  
Richard Semba ◽  
Newton Kumwenda ◽  
Taha Taha ◽  
Laban Mtimavalye ◽  
Robin Broadhead ◽  
...  
Keyword(s):  
Breast Milk ◽  
Vitamin A ◽  
Pregnant Women ◽  
Acute Phase ◽  
Acute Phase Proteins ◽  
Post Partum ◽  
Controlled Trial ◽  
Geometric Mean ◽  
Vitamin A Status ◽  
Plasma Retinol

Breast milk vitamin A is not well characterized as an indicator of vitamin A status in women with infections. A controlled trial of vitamin A, 3 mg retinol equivalent/day, was conducted among 697 pregnant women with human immunodeficiency virus (HIV) infection in Malawi which allowed comparison of plasma versus breast milk vitamin A as indicators of vitamin A status. Retinol concentrations were measured in plasma at baseline (18–28 weeks) and 38 weeks gestation and breast milk at 6 weeks post-partum. Plasam a1-acid glycoprotein (AGP) and C-reactive protein (CRP) were measured at baseline. Plasma retinol (geometric mean, SD) at 38 weeks was 0.72 (0.44, 1.18) and 0.61 (0,38, 0.98) mmol/L (P < 0.0002) and breast milk retinol was 1.32 (0.71, 2.43) and 0.95 (0.49, 1.82) mmol/L (P < 0.0001) in vitamin A and placebo groups, respectively. Women with elevated acute phase protein (AGP > 1 gm/L and/or CRP > 5 mg/L) at baseline who received vitamin A had significantly higher plasma and breast milk vitamin A at follow-up compared with placebo, Elevated acute phase proteins did not distinguish women with low body stores of vitamin A. Breast rnilk retinol appears to be a better indicator of vitamin A status than plasma retinol in women with infections.

scholarly journals POS1036 COLLAGEN TURNOVER MARKERS ARE ASSOCIATED WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT IN A PHASE-3 CLINICAL TRIAL

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 790.2-792
Author(s):  
G. Schett ◽  
M. J. Loza ◽  
A. Palanichamy ◽  
O. Fitzgerald ◽  
C. T. Ritchlin ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Structural Damage ◽  
Signs And Symptoms ◽  
Joint Disease ◽  
Type I ◽  
Healthy Controls ◽  
Phase 3 ◽  
Two Phase ◽  
Radiographic Damage ◽  
Collagen Formation

Background:Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active psoriatic arthritis (PsA) in two phase-3 studies, DISCOVER-1 & -2, and in retarding structural damage in DISCOVER-2.1,2Objectives:To evaluate tissue-derived extracellular matrix (ECM) products3,4 in serum of PsA patients in the DISCOVER-2 study and their relationship with radiographic damage, clinical response, and impact of treatment.Methods:In DISCOVER-2, patients were treated with GUS 100 mg at Week (w) 0, 4, then every 8w (q8w); GUS 100 mg every 4w (q4w); or matching PBO. At w24, PBO patients were crossed over to GUS q4w. A total of 11 serum biomarkers of ECM collagen formation (PRO-C1, PRO-C2, PRO-C3, PRO-C4, and PRO-C6) and degradation (C1M, C2M, C3M, C4M, C6M, and COL10) were measured (by Nordic Bioscience) in a subset of 260 patients from the DISCOVER-2 program at Weeks 0, 4, 24, & 52 and in 76 healthy controls matched for age, sex, and ethnicity. PsA patients were selected randomly, though enriching for subjects with greatest radiographic changes, at Weeks 24 and 52. Significance defined by p<0.05 and |fold difference| ≥1.25.Results:At baseline, collagen degradation markers C1M, C3M, C4M, C6M and collagen formation markers PRO-C3 and PRO-C6 were significantly higher in the serum of PsA patients compared to matched healthy controls. Baseline C3M, C4M, and C6M were positively correlated to baseline skin and joint disease; baseline C1M, C3M, C4M, C6M, and PRO-C1 were positively correlated to baseline radiographic damage (data not shown). Levels of C1M (a maker indicating breakdown of collagen type I, the major collagen subtype in the bone) were significantly decreased after 24w treatment with GUS (Figure 1), reaching significant differences from placebo with the GUS 100 mg q4w group. For the PBO patients who crossed over to GUS at w24, there was also a reduction in this marker observed at w52 (Figure 1). In patients treated with GUS or PBO, there were no significant differences in baseline expression levels of the analytes in responders (patients achieving ACR20 at w24) compared with non-responders. However, ACR20 responders in the combined GUS group had a significantly greater reduction in C1M levels compared to non-responders (p=0.0065) at w24.Conclusion:This work provides evidence that collagen biomarkers in serum are dysregulated in patients with PsA compared to healthy controls, and that GUS impacts levels of these proteins. Importantly, C1M serves as a biomarker that tracks with joint response. We observed a greater reduction in C1M in ACR responders compared to non-responders, providing insight into how GUS may be working to protect from degradation of bone in PsA.References:[1]Deodhar A et al. Lancet 2020;395:1115-1125[2]Mease PJ et al. Lancet 2020;395:1126-1136[3]Gudmann NS et al. Clin Exp Rheumatol 2017;35:653-659[4]Sardar S et al. Annals of the Rheum Dis 2019;78(Suppl 2): https://ard.bmj.com/content/78/Suppl_2/867.1Disclosure of Interests:Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche, UCB, Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche, UCB, Matthew J Loza Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Arumugam Palanichamy Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Oliver FitzGerald Speakers bureau: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Consultant of: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Christopher T. Ritchlin Speakers bureau: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Frederic Baribaud Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Kristen Sweet Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC.

scholarly journals Selected serum biochemical parameters and acute phase protein levels in a herd of Saanen goats showing signs of pregnancy toxaemia

2014 ◽  
Vol 59 (No. 7) ◽  
pp. 336-342 ◽  
Author(s):  
MK Albay ◽  
MC Karakurum ◽  
S. Sahinduran ◽  
K. Sezer ◽  
R. Yildiz ◽  
...  
Keyword(s):  
Acute Phase ◽  
Acute Phase Proteins ◽  
Acute Phase Protein ◽  
Serum Glucose ◽  
Protein Levels ◽  
Serum Biochemical ◽  
Group 3 ◽  
Group 2 ◽  
Pregnancy Toxaemia ◽  
Group 1

The purpose of this study was to examine selected serum biochemical parameters and acute phase protein levels in a herd of Saanen goats showing signs of pregnancy toxaemia. Seventy five female goats were used and divided into three groups. Group 1 (n = 57) (blood serum glucose levels were within the physiological range), Group 2 (n = 11) (serum glucose values were low) and Group 3 (n = 7) (serum glucose values were high). Goats in Groups 2 and 3 were diagnosed with pregnancy toxaemia. Apart from serum glucose, &beta;-hydroxybutyrate (BHB), triglycerides, blood pH, calcium (Ca), sodium (Na), potassium (K), aspartate aminotransferase (AST), alanine aminotransferase (ALT), haptoglobin (Hp), serum amyloid A (SAA) and tumour necrosis factor-&alpha; (TNF-&alpha;) were measured in all animals. In Group 3 average Hp and SAA values were found to be significantly (P &lt; 0.001) higher than in Groups 1 and 2, and also higher in Group 2 than in Group 1. Acute phase proteins in goats with pregnancy toxaemia may be used in the course and the prognosis of the disease. The evaluation of acute phase proteins is useful and also quicker in cases of suspected pregnancy intoxication.

Disease Characteristics and Burden in Patients With Atopic Dermatitis: Insights From Two Phase 3 Studies of Ruxolitinib Cream

2021 ◽  
Vol 147 (2) ◽  
pp. AB35
Author(s):  
Eric Simpson ◽  
Mark Lee ◽  
Kanwaljit Brar ◽  
Michael Kuligowski ◽  
May Venturanza ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Phase 3 ◽  
Two Phase ◽  
Disease Characteristics

Similarities in acute phase protein response during hibernation in black bears and major depression in humans: a response to underlying metabolic depression?

2004 ◽  
Vol 82 (9) ◽  
pp. 1468-1476 ◽  
Author(s):  
John A Tsiouris ◽  
Ved P.S Chauhan ◽  
Ashfaq M Sheikh ◽  
Abha Chauhan ◽  
Mazhar Malik ◽  
...  
Keyword(s):  
Major Depression ◽  
Acute Phase ◽  
Acute Phase Proteins ◽  
Mild Hypothermia ◽  
Black Bears ◽  
Metabolic Depression ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Serial Samples

This study investigated the effects of hibernation with mild hypothermia and the stress of captivity on levels of six acute-phase proteins (APPs) in serial samples of serum from 11 wild and 6 captive black bears (Ursus ameri canus Pallas, 1780) during active and hibernating states. We hypothesize that during hibernation with mild hypothermia, bears would show an APP response similar to that observed in major depression. Enzyme-linked immuno absorbent assay was used to measure alpha2-macroglobulin and C-reactive protein, and a nephelometer to measure alpha1-antitrypsin, hapto globin, ceruloplasmin, and transferrin. Levels of all other proteins except ceruloplasmin were significantly elevated during hibernation in both wild and captive bears at the p < 0.05 to p < 0.001 level. Alpha2-macroglobulin and C-reactive-protein levels were increased in captive versus wild bears in both active and hibernating states at the p < 0.01 to p < 0.0001 level. During hibernation with mild hypothermia, black bears do not show immunosuppression, but show an increased APP response similar to that in patients with major depression. This APP response is explained as an adaptive response to the underlying metabolic depression in both conditions. Metabolic depression in hibernating bears is suggested as a natural model for research to explain the neurobiology of depression.

scholarly journals Acute phase proteins and biochemical and oxidative stress parameters in Hypoderma spp. infested cattle

2018 ◽  
Vol 68 (4) ◽  
pp. 535 ◽  
Author(s):  
O. MERHAN ◽  
K. BOZUKLUHAN ◽  
H. I. GOKCE
Keyword(s):  
Oxidative Stress ◽  
Acute Phase ◽  
Whole Blood ◽  
Total Protein ◽  
Acute Phase Proteins ◽  
Control Group ◽  
Blood Samples ◽  
Protein Levels ◽  
Amyloid A ◽  
And Oxidative Stress

The aim of the present study was to determine concentrations of acute phase proteins (APP), oxidative stress and some biochemical parameters in naturally infested cattle with Hypoderma spp. For this purpose, 10 clinically healthy cattle as controls and 25 Brown Swiss cattle with Hypoderma spp. were used. Blood samples were collectedto tubes from jugular vein. Parts of blood samples were stored without any process as a whole blood. The serum was separated from the remaining blood samples. The reduced glutathione (GSH) in whole blood and the level of malondialdehyde (MDA), haptoglobin (Hp), ceruloplasmin, serum amyloid A (SAA), AST, GGT, ALP, CK, albumin, urea and total protein levels in serum were colorimetrically determined. The present study indicated that the concentrations of Hp, SAA, ceruloplasmin, AST, GGT, ALP, CK, and MDA were significantly increased, and albumin, total protein, GSH concentrations were significantly decreased in the Hypoderma spp. infested group compared to the control group. Additionally, the increase in serum Hp levels was proportional to the number of Hypoderma spp. and it was statistically significant. In conclusion, the production of APP increased in a response to acute phase response in animals with subcutaneous warbles. Furthermore, liver functions were also shown to be impaired and oxidative stress developed as a result of metabolic products of the parasite in Hypoderma spp. infested cattle.

scholarly journals Effects of selected nonsteroidal anti-inflammatory drugs on acute-phase protein levels after dehorning in Holstein heifers

2019 ◽  
Vol 75 (05) ◽  
pp. 6265-2019
Author(s):  
HASAN ERDOGAN ◽  
IBRAHIM AKIN ◽  
KEREM URAL ◽  
PINAR ALKIM ULUTAS
Keyword(s):  
Acute Phase ◽  
Serum Amyloid A ◽  
Acute Phase Proteins ◽  
Serum Amyloid ◽  
Mean Values ◽  
Protein Levels ◽  
Amyloid A ◽  
Flunixin Meglumine ◽  
Significant Difference ◽  
Inflammatory Drugs

The purpose of this study was to evaluate the effects of ketoprofen (KTP), flunixin meglumine (FLM), and meloxicam (MLX) administration on acute-phase proteins after dehorning in Holstein heifers. A total of 21 Holstein heifers were enrolled into three groups of equal size (n=7) and administered ketoprofen, flunixin meglumine, or meloxicam, at doses of 2.2 mg/kg, 1.1 mg/kg, and 1 mg/kg body weight, respectively. Serum amyloid A, haptoglobin, and ceruloplasmin levels were determined before the administration of the three drugs (0 hrs) and at 6, 12, 24, 48, and 96 hours post-administration. The mean values (±SD) obtained revealed no significant alteration in APP levels at 0 hrs in any of the three groups. Time-dependent alterations, however, were significant in all groups. Group-time interactions were significant (P < 0.001) for ceruloplasmin concentrations, whereas results for serum amyloid A and haptoglobin levels were deemed non-significant. Inter-group interaction revealed no significant findings regarding serum amyloid A and ceruloplasmin levels, but haptoglobin levels showed a significant difference between the KTP and FLM groups at 48 hrs. It may therefore be reasonably suggested that KTP, FLM, and MLX could all be administered to effect slight changes in acute phase proteins.

Sign in / Sign up

Export Citation Format

Share Document